SCHEMBL29324265

SCHEMBL29324265

Cc1cc(F)c2cc(C(C)(C)C)ccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
CCNE2 O96020 1/20 0.40
CCNA2 P20248 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
DHODH Q02127 1/20 0.40
TNKS O95271 1/20 0.40
PARP1 P09874 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GAK O14976 1/20 0.39
SLC2A1 P11166 1/20 0.39
LMNA P02545 1/20 0.39
PTGFR P43088 1/20 0.38
SCD O00767 1/20 0.38
ALOX5AP P20292 1/20 0.38
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29324280 0.82 CYP1A2 (0.58) CYP1A2L3MBTL1MEN1KMT2AGAK
SCHEMBL29324282 0.77 DOT1L (0.53) MEN1KMT2AGAKSLC2A1LMNA
SCHEMBL13758123 0.75 LMNA (0.41) CYP1A2L3MBTL1PARP1LMNAPTGFR
SCHEMBL21849329 0.73 POLB (0.59) CYP1A2MEN1KMT2ASLC2A1KCNH2
SCHEMBL6195465 0.72 CYP1A2 (0.64) CYP1A2L3MBTL1MEN1KMT2AKDM4E
SCHEMBL23858583 0.71 TDP1 (0.53) L3MBTL1MEN1KMT2ALMNAPOLB
SCHEMBL30251698 0.71 TDP1 (0.53) L3MBTL1MEN1KMT2ALMNAPOLB
SCHEMBL28910028 0.71 IDO1 (0.44) CYP1A2MEN1KMT2ALMNAPOLB
SCHEMBL28937451 0.71 PSMB5 (0.39) CYP1A2L3MBTL1MEN1KMT2ASLC2A1
SCHEMBL20043182 0.71 KCNH2 (0.42) L3MBTL1MEN1KMT2ALMNASCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CYP1A2 424/4885L3MBTL1 403/4885CCNE2 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.